First Author: M.Gajdosova SLOVAKIA
Co Author(s): R. Pejchalova L. Katrinakova M. Ondrejkova
Back to previous
To evaluate the efficacy of aflibercept in eyes with diabetic macular edema (DME)
OFTAL s.r.o, Specialised Hospital for Ophtalmology, Zvolen, Slovakia
Retrospective analysis of 48 eyes of 36 patients (20 (55%) men, 16 (45%) women), mean age 65,1 years, mean follow up 16,1 (12-23) months, treated with aflibercept according to SPC (loading dose 5 injections monthly, then every two months) at least 12 monhts. We analysed functional (BCVA - ETDRS letters), anatomical (CRT- um) results and adverse events.
From 48 eyes evaluated, 11 (23%) eyes were treatment naive, 37 (77%) were switched from other IVT therapies (ranibizumab, bevacizumab, triamcinolon) Treatment naive: Mean BCVA change was +4,8 letters after 3 months, +7,3 letters at 6 and +10,3 letters at 12 months. At 12 months gain more than 15 letters had 27,3% eyes and more than 10 letters 45,4% eyes. Mean CRT change was -137,5 um after 3 months, -146,2 um at 6, -177,3 um at 12 months. Switched: Mean BCVA change was +3 letters after 3 months, +1,6 letters at 6 and +3,7 letters at 12 months. At 12 months gain more than 15 letters had 10,8% eyes and more than 10 letters 5,4% eyes. Mean CRT change was -83,5 µm after 3 months, -73,3 µm at 6 -105 µm at 12 months.
Aflibercept represents safe and effective therapeutic option for eyes with DME. It significantly improves visual acuity in treatment naive eyes and brings also the functional benefit to eyes without any or little effect after previous treatments.